Psyence BioMed Signs Binding Term Sheet for Exclusive U.S. Ibogaine License
Key Points
- TIRC and PsyLabs aim to sign a definitive agreement by November 30, 2026. If they do not, the binding term sheet will lapse.
- The proposed license covers PsyLabs’ ibogaine-related technical information and methods for developing, manufacturing and commercializing U.S. drug candidates.
- TIRC would pay up to approximately $1.3 million in development and regulatory milestones for the first drug candidate, plus potential royalties and other payments.
- PsyLabs is a significant shareholder of Psyence BioMed, and Psyence BioMed also holds an ownership interest in PsyLabs.
- A U.S. clinical investigation is not yet underway; TIRC must first complete manufacturing, nonclinical and regulatory work.
Psyence Biomedical Ltd. (NASDAQ: PBM) announced its wholly owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), has signed a binding term sheet with Psyence Labs Ltd. (PsyLabs) for exclusive U.S. rights related to PsyLabs’ pharmaceutical-grade ibogaine. The arrangement would give TIRC access to manufacturing and regulatory know-how, as well as exclusive U.S. supply and distribution rights, but it still requires a definitive agreement.
Exclusive U.S. License Would Cover Ibogaine Development and Distribution
Under the term sheet, PsyLabs would license TIRC its ibogaine-related know-how, trade secrets, production methods, specifications, records and technical and regulatory information for use in the United States. PsyLabs would serve as TIRC’s exclusive ibogaine supplier, while TIRC would become PsyLabs’ exclusive U.S. wholesaler and distributor. PsyLabs would retain rights outside the United States.
The proposed exclusivity is conditional. TIRC would generally need to source all its U.S. ibogaine requirements from PsyLabs, subject to supply-failure protections. The definitive agreement is also expected to set minimum development or sales performance thresholds.
License Terms Include Milestones, Royalties and Fees
For the first drug candidate, TIRC would owe PsyLabs development and regulatory milestone payments totaling up to approximately $1.3 million. The terms also call for a low-single-digit royalty on net sales of each drug candidate, an annual exclusivity fee beginning on the first anniversary of the first FDA approval, and margin sharing on any product TIRC resells. The annual fee would be creditable against royalties.
Psyence BioMed describes PsyLabs as licensed in its operating jurisdiction to cultivate, extract and export ibogaine, with production and processing at an ISO 22000 and GMP-compliant facility. The announcement does not say that a TIRC ibogaine drug candidate has FDA approval.
Investor Takeaway: U.S. Rights Are Defined, but Development Is Early
For PBM investors, the term sheet outlines a potential U.S. position in ibogaine development and sets out the associated supply relationship and payment obligations. It does not establish an approved treatment or an imminent commercial launch.
The first milestone to watch is whether TIRC and PsyLabs execute the definitive agreement by November 30. After that, progress depends on manufacturing, nonclinical and regulatory work before TIRC can propose a U.S. clinical investigation. Investors should also note the relationship between the parties: PsyLabs is both a significant Psyence BioMed shareholder and a company in which Psyence BioMed owns an interest.
